It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly stock has generated fantastic returns for investors over the past five years. The company possesses many lucrative growth opportunities to ensure it remains an excellent buy in the years ...

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24 ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

Dr Reddy’s Laboratories is also working on a generic version of Wegovy. (Image/Getty) US pharma major Eli Lilly on Thursday launched its global bestseller anti-obesity and diabetes drug Mounjaro ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market with a large obese population. This move positions ...